1. 2019
  2. Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented in Vitro by Adequate Activating Signaling

    Hofland, T., Endstra, S., Gomes, C. K. P., de Boer, R., de Weerdt, I., Bobkov, V., Riedl, J. A., Heukers, R., Smit, M. J., Eldering, E., Levin, M-D., Kater, A. P. & Tonino, S. H., 1 Dec 2019, In: HemaSphere. 3, 6, e308.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Rare but Serious: Ibrutinib Induced Liver Failure

    Kleijwegt, F. S., Roda, A. A., Rolvink, J., Kater, A. P., Kersten, M. J. & Vos, J. M. I., 1 Dec 2019, In: HemaSphere. 3, 6, p. e307

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

    Deng, R., Gibiansky, L., Lu, T., Agarwal, P., Ding, H., Li, X., Kshirsagar, S., Lu, D., Li, C., Girish, S., Wang, J., Boyer, M., Humphrey, K., Freise, K. J., Salem, A. H., Seymour, J. F., Kater, A. P. & Miles, D., Dec 2019, In: Clinical pharmacokinetics. 58, 12, p. 1621-1634

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study

    Ruchlemer, R., Ben-Ami, R., Bar-Meir, M., Brown, J. R., Malphettes, M., Mous, R., Tonino, S. H., Soussain, C., Barzic, N., Messina, J. A., Jain, P., Cohen, R., Hill, B., Mulligan, S. P., Nijland, M., Herishanu, Y., Benjamini, O., Tadmor, T., Okamoto, K., Arthurs, B., & 9 othersGottesman, B., Kater, A. P., Talha, M., Eichhorst, B., Korem, M., Bogot, N., de Boer, F., Rowe, J. M. & Lachish, T., Dec 2019, In: Mycoses. 62, 12, p. 1140-1147

    Research output: Contribution to journalArticleAcademicpeer-review

  6. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

    Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J. K., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., le Gouill, S., Oberic, L., Robak, T., & 7 othersJain, P., Frigault, M. M., Izumi, R., Nguyen, D., Patel, P., Yin, M. & Długosz-Danecka, M., Nov 2019, In: Leukemia. 33, 11, p. 2762-2766

    Research output: Contribution to journalComment/Letter to the editorAcademic

  7. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

    de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M-D., Eldering, E., Tonino, S. H. & Kater, A. P., 10 Sep 2019, In: Blood advances. 3, 17, p. 2642-2652 11 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?

    de Weerdt, I. & Kater, A. P., 1 Jun 2019, In: HemaSphere. 3, S2, p. 44-46

    Research output: Contribution to journalArticleAcademicpeer-review

  9. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

    Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., Wang, J., Boyer, M., Humphrey, K., Mobasher, M. & Kipps, T. J., 1 Feb 2019, In: Journal of clinical oncology. 37, 4, p. 269-277 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  10. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Leeksma, A. C., Taylor, J., Wu, B., Gardner, J. R., He, J., Nahas, M., Gonen, M., Alemayehu, W. G., te Raa, D., Walther, T., Hüllein, J., Dietrich, S., Claus, R., de Boer, F., de Heer, K., Dubois, J., Dampmann, M., Dürig, J., van Oers, M. H. J., Geisler, C. H., & 11 othersEldering, E., Levine, R. L., Miller, V., Mughal, T., Lamanna, N., Frattini, M. G., Heaney, M. L., Zelenetz, A., Zenz, T., Abdel-Wahab, O. & Kater, A. P., Feb 2019, In: Leukemia. 33, 2, p. 390-402 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  11. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

    JULIET Investigators, Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & 18 othersAwasthi, R., Chu, J., Anak, Ö., Salles, G., Maziarz, R. T., Study group members AMC, Kersten, M. J. J., Biemond, B. J., Burger, P., Claessen, M-J. J. A. G., Hazenberg, M. D., Kater, A. P., Kemper, E. M., Nur, E., Spiering, M., Tonino, S. H., Voermans, C. & Zeerleder, S. S., 3 Jan 2019, In: New England journal of medicine. 380, 1, p. 45-56 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1...3 4 5 6 7 8 9 10 ...20 Next

ID: 64520